Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
284 Chapter 23 · Emergencies in <strong>Acute</strong> Lymphoblastic Leukemia<br />
preinduction therapy with glucocorticoids, adding vincristine<br />
and cyclophosphamide in cases of B-cell ALL, is<br />
a preferred means for the amelioration of hyperleukocytosis<br />
[46, 47]. Preinduction chemotherapy in combination<br />
with urate oxidase has dramatically decreased the<br />
frequency of tumor lysis syndrome and the need for hemodialysis<br />
in patients with B-ALL [48].<br />
If administration of chemotherapy is not feasible in<br />
a patient with hyperleukocytosis and symptoms of<br />
leukostasis, or it must be delayed secondary to the significant<br />
metabolic abnormalities, renal insufficiency, or<br />
possibly pregnancy, emergency leukapheresis may be<br />
used to decrease or stabilize WBC count. However, based<br />
on the available data, leukapheresis cannot be recommended<br />
as a routine therapy or as a form of tumor debulking<br />
in an asymptomatic adult patient with ALL.<br />
23.6 SVC/Mediastinal Mass<br />
Patients with ALL (particularly T-ALL) may present<br />
with symptoms of cough, dyspnea, stridor, or dysphagia<br />
from the tracheal and esophageal compression by a mediastinal<br />
mass. More than 27% of children who presented<br />
with mediastinal mass have acute airway compromise<br />
[49]. Compression of great vessels by a bulky<br />
mediastinal mass may also lead to the life-threatening<br />
superior vena cava syndrome. In addition to the<br />
above-mentioned symptoms, patients might develop cyanosis,<br />
facial edema, increased intracranial pressure,<br />
and syncope.<br />
The prognosis of patients with SVC syndrome is<br />
strongly correlated with the prognosis of underlying<br />
disease. Diagnosis of primary condition must be established<br />
promptly, and therapy with steroids, radiation,<br />
and/or chemotherapy must be initiated without delay.<br />
When the therapeutic goal is only palliation of SVC syndrome,<br />
or if emergent treatment of the venous obstruction<br />
is required, direct opening of the occlusion with endovascular<br />
stenting and angioplasty with possible<br />
thrombolysis should provide prompt relief of symptoms<br />
[50]. Other medical measures such as head elevation<br />
and oxygen administration, which can reduce cardiac<br />
output and venous pressure, might be helpful.<br />
23.7 DIC<br />
Disseminated intravascular coagulation (DIC) is a<br />
known complication of ALL in children [51–53] and<br />
adults [54]. The frequency of DIC in adults is reported<br />
to be 10–16% at presentation and 36–78% during remission<br />
induction therapy [55–57]. Hypofibrinogenemia<br />
(< 100 mg/dl) was detected in 41% of patients with<br />
ALL at the time of diagnosis and after initiation of therapy<br />
[58]. Hemorrhagic symptoms are usually mild;<br />
however, serious hemorrhage occurs in 20% of patients<br />
with laboratory evidence of DIC [55].<br />
Patients who develop DIC tend to have a higher<br />
WBC (77900/mm 3 vs. 9400/mm 3 ) counts and a higher<br />
frequency of palpable splenomegaly than the patients<br />
who do not develop DIC. However, no statistically significant<br />
relationship was established between DIC and<br />
age, FAB subtype, immunophenotype, karyotype,<br />
LDH, and percentage of blasts in the bone marrow.<br />
An etiologic link between CD34 expression and DIC<br />
has been suggested [57].<br />
ALL patients who developed DIC after the initiation<br />
of chemotherapy had a lower platelet level and higher<br />
level of the E-fragment of serum fibrinogen/fibrin degradation<br />
products (FDP) at presentation, suggesting<br />
that they already had DIC at presentation. These findings<br />
indicate that perhaps patients with high WBC<br />
counts, higher FDP level, a low platelet count, and splenomegaly<br />
at presentation require closer monitoring for<br />
DIC after the initiation of chemotherapy.<br />
The best way to treat DIC is to treat the underlying<br />
ALL. However, exacerbation of DIC may occur during<br />
induction therapy and with ATLS.<br />
The coagulation profile must be obtained at the time<br />
of diagnosis and repeated frequently, especially when<br />
laboratory evidence of DIC is detected, to guide the<br />
replacement therapy in DIC. Theoretical concerns for<br />
exacerbating DIC with blood products have not been<br />
substantiated clinically, and hemostatic competence to<br />
avoid severe bleeding must be maintained. It is reasonable<br />
to keep activated partial thromboplastin time<br />
(aPTT) at about 1.5 times normal level with FFP, platelets<br />
at about 50000/ll with platelet transfusions, and<br />
fibrinogen level over 100 mg/dl with cryoprecipitate.<br />
Heparin therapy is rarely indicated in the patient with<br />
ALL and DIC. However, if required, heparin levels<br />
should be followed, since the monitoring aPTT may lead<br />
to over- or under-treatment of the patient.